Navigation Links
7 SynCardia Certified Centers Honored Among “Best Children’s Hospitals” for Cardiology and Heart Surgery by U.S. News & World Report
Date:6/13/2013

Tucson, Ariz. (PRWEB) June 13, 2013

SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that U.S. News & World Report has named seven SynCardia Certified Centers among the nation's "Best Children's Hospitals" for cardiology and heart surgery in its annual rankings for 2013-2014.

“The SynCardia temporary Total Artificial Heart has opened the floodgates in respect to the treatment possibilities for a quickly growing population of children in heart failure, including adolescents suffering from chronic rejection of their transplanted heart, end-stage heart failure accompanied by multiple congenital defects and a late-stage failing Fontan circulation,” said Dr. David L.S. Morales, chief of pediatric cardiothoracic surgery at Cincinnati Children’s Hospital Medical Center, which ranked in the top five.

SynCardia Certified Centers included in the list were:

•#2 Children's Hospital of Philadelphia (CHOP)
•#3 Texas Children's Hospital
•#5 Cincinnati Children’s Hospital Medical Center
•#11 Children’s Hospital of Wisconsin
•#26 Mattel Children’s Hospital UCLA
•#32 Shands Hospital for Children at the University of Florida
•#34 Phoenix Children’s Hospital

In addition to the seven hospitals listed above, #9 Lucile Packard Children’s Hospital at Stanford and #43 Arkansas Children’s Hospital have completed the first two phases of SynCardia’s four-phase certification program and are ready to perform their first proctored implant once an appropriate patient has been identified.

Clinical research, surgical survival and ability to prevent bloodstream infections were among the factors making up 75% of the score used for the rankings. The other 25% reflects how many of 450 pediatric cardiologists and heart surgeons surveyed in 2011, 2012 and 2013 recommended the hospital.

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,100 implants of the Total Artificial Heart, accounting for more than 300 patient years of life.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes ranks SynCardia #69 Among “America’s Most Promising Companies”.

In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.

Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia

Read the full story at http://www.prweb.com/releases/2013/6/prweb10829106.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. SynCardia Total Artificial Heart Bridges Former Semi-Pro Arena Football Player to Heart Transplant
2. SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre
3. Nebraska Medical Center Implants States First SynCardia Total Artificial Heart
4. University of Kentucky Medical Center Transplants States 1st SynCardia Total Artificial Heart Patient
5. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
6. 2012 American Business Awards?Honors SynCardia with Two Gold Stevie® Awards
7. CE Certified Differentiated Drain Application Patent To Be Auctioned Through IpAuctions, Inc.
8. Project Oncology CME Series Launches on ReachMD, Offering Learners a Wide Array of Certified Oncology Activities Across an Integrated Platform
9. Fidelis Companies Certifies 14 Recruiters; Certified Personnel Consultant (CPC) and Certified Temporary-Staffing Specialist (CTS) Designation from NAPS Awarded
10. Soltex Consulting Certified as a Woman Business Enterprise
11. iLuv Introducing NFC & Qi-Certified Technology to Bluetooth Speaker Lineup at 2013 CES
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  In the pharmaceutical industry the medical affairs ... launch activities including the identification and engagement of key ... especially high in the oncology therapeutic area where most ... the Role of Medical Affairs in Oncology Launch Excellence ... therapies find better ways to utilize medical affairs to ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... compliance training, today announced an interactive FDA compliance training course, ... (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available on ...
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> --> Fourth ... (105.0), up 1,187% compared with fourth quarter of 2014. Gross ... M (loss: 30.0). Earnings per share increased to SEK 6.39 ... M (neg: 74.7). , --> ... SEK 2,900.5 M (233.6), up 1,142% compared with 2014. Gross ...
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
Breaking Biology News(10 mins):